Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation

Another autograft or switch to allograft?

C. O. Freytes, H. M. Lazarus

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.

Original languageEnglish (US)
Pages (from-to)559-569
Number of pages11
JournalBone Marrow Transplantation
Volume44
Issue number9
DOIs
StatePublished - 2009

Fingerprint

Autologous Transplantation
Autografts
Allografts
Lymphoma
Recurrence
Antineoplastic Agents
Tissue Donors
Clinical Trials
Transplants
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation : Another autograft or switch to allograft? / Freytes, C. O.; Lazarus, H. M.

In: Bone Marrow Transplantation, Vol. 44, No. 9, 2009, p. 559-569.

Research output: Contribution to journalArticle

@article{d97030ba755c43baa97405efdc6f4edf,
title = "Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: Another autograft or switch to allograft?",
abstract = "Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.",
author = "Freytes, {C. O.} and Lazarus, {H. M.}",
year = "2009",
doi = "10.1038/bmt.2009.214",
language = "English (US)",
volume = "44",
pages = "559--569",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation

T2 - Another autograft or switch to allograft?

AU - Freytes, C. O.

AU - Lazarus, H. M.

PY - 2009

Y1 - 2009

N2 - Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.

AB - Although autologous hematopoietic SCT (auto-HSCT) is the only potentially curative treatment for lymphoma that has relapsed after conventional chemotherapy, the prognosis of patients with disease recurrence after auto-HSCT is poor. Some highly selected patients can benefit from second transplants. One-third with late recurrence after initial auto-HSCT may attain a prolonged remission after second auto-HSCT. Non-myeloablative or reduced-intensity conditioning (RIC) allogeneic hematopoietic SCT (allo-HSCT) has been used successfully after auto-HSCT failures, especially in subjects who have an HLA-compatible donor, chemosensitive disease and good performance status. Patients with chemosenstive disease recurrence who have completed at least 1 year after their first auto-HSCT should be considered for a second auto-HSCT. Patients who have chemoresistant disease are best served by participation in a well-designed clinical trial examining novel antitumor agents.

UR - http://www.scopus.com/inward/record.url?scp=70749090444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749090444&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.214

DO - 10.1038/bmt.2009.214

M3 - Article

VL - 44

SP - 559

EP - 569

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -